RedChip Companies, Inc.: Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV

RedChip Companies said Foremost Clean Energy (Nasdaq:FMST, CSE:FAT) and BioVie (Nasdaq:BIVI) will be featured on its “RedChip Small Stocks, Big Money” show on Bloomberg TV on May 30 at 7 p.m. ET. Foremost’s CEO discussed its Hatchet Lake uranium discovery and Denison partnership; BioVie’s CEO discussed bezisterim clinical readouts expected by end of summer/early fall.

Original reporting
Published May 29, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 2:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RedChip Companies, Inc.: Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV — source image
Decision brief

The 30-second read

$FMSTBullishLow
01

Why it matters

The text emphasizes exploration and clinical milestone timing but does not provide fresh quantitative results; impact is mainly sentiment/catalyst-awareness rather than a fundamental reprice trigger.

02

Market read

Both FMST and BIVI are positioned around near-term narrative catalysts (drilling/discovery momentum; clinical readout windows) promoted via Bloomberg TV.

03

What to watch

Traders may overreact to “high-grade discovery” or “catalyst timing” without new disclosed metrics (assay grades, enrollment numbers, response rates).

Relevance 6/10Novelty 4/10Timing: Ahead of the May 30 Bloomberg TV interview; readouts discussed for end of summer/early fall.

Background

RedChip Companies will air interviews on Bloomberg TV featuring Foremost Clean Energy’s uranium/lithium story and BioVie’s bezisterim clinical development progress.

Company-level read

Ticker impact

$FMSTBullishMedium confidence
Context

Foremost Clean Energy discusses a recent high-grade uranium discovery at Hatchet Lake and its Denison partnership on Bloomberg TV.

Expected impact

Near-term sentiment support possible, but no new drill results or quantified updates are provided in the text.

Evidence & confidence

It signals continued exploration momentum (discovery/high-grade, multiple drill programs) yet functions mainly as a promotional interview notice without incremental data.

$BIVIBullishMedium confidence
Context

BioVie highlights clinical progress for bezisterim (NE3107), including Parkinson’s patient-facing activity completion and Long COVID enrollment.

Expected impact

Potential sympathy bid into the stated readout window, though details are not new trial datapoints.

Evidence & confidence

It provides timing (end of summer/early fall) and trial milestones, but the article is still an interview announcement rather than a results release.

Market effects

Reinforces ongoing investor focus on uranium supply security and neuroinflammation/insulin-resistance drug development narratives.

No direct regional macro linkage beyond Saskatchewan uranium and Manitoba lithium project references.

Ties demand themes to AI/data centers and electrification for nuclear, and to Long COVID/Parkinson’s unmet need for biotech.

Counterpoint

Because this is a sponsored interview announcement, it may not contain incremental, decision-grade information versus what the market already expects.

Key entities

  • Foremost Clean Energy Ltd.

    Uranium and lithium exploration company; discusses Hatchet Lake high-grade discovery and Denison partnership.

  • BioVie, Inc.

    Clinical-stage biopharma; discusses bezisterim (NE3107) Parkinson’s and Long COVID trial milestones.

  • Denison Mines

    Partner providing technical expertise/financial support under an earn-up-to interest arrangement with Foremost.

Related articles

$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

$BIVIMedAI 8/10

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI) reported positive Phase 2 SUNRISE-PD results for its Parkinson's candidate bezisterim. The drug met prespecified endpoints in early-stage, untreated patients, improving blood inflammatory markers and EPNIC-15 versus placebo. Benefits were strongest in patients with higher baseline platelet counts. Safety was similar to placebo, with 39.3% adverse events vs 51.7%.

$FMSTMed

Foremost Clean Energy To Earn Majority Interest Across Athabasca Uranium Portfolio Under Denison Option Agreement

Foremost Clean Energy Ltd. (NASDAQ: FMST, CSE: FAT) said it completed Phase 2 of a three-phase earn-in option with Denison Mines Corp. It will issue Denison up to 848,610 shares valued at $2 million. Foremost reports $8 million in qualifying exploration spending and expects majority ownership of 51% across 10 Athabasca uranium projects, except Hatchet Lake at 35.78%, about 15 months ahead of the Oct 2027 deadline.

$FMSTMed

Foremost Clean Energy Ltd.: Foremost Clean Energy To Earn Majority Interest Across Athabasca Uranium Portfolio Under Denison Option Agreement

Foremost Clean Energy Ltd. (NASDAQ: FMST, CSE: FAT) said it completed Phase 2 of a Denison option agreement, issuing up to 848,610 shares valued at $2 million. After Phase 2, it expects 51% ownership across 10 Athabasca uranium projects (35.78% at Hatchet Lake), after $8 million in qualifying exploration, about 15 months ahead of Oct 2027.

$BIVIMedAI 9/10

BioVie: Long COVID trial fully enrolled – ICYMI

BioVie Inc (NASDAQ:BIVI) said its Phase 2 long COVID trial of bezisterim is fully enrolled, with more than 200 patients randomized to placebo or bezisterim. CEO Cuong Do said the study includes sites such as Yale, Mount Sinai, Mayo Clinic and Stanford, targeting symptoms like brain fog, malaise and fatigue. Top-line results are expected by late October or as early as September; the company plans FDA discussions on accelerated approval or EUA if data support benefit-risk.